MEDICI: Mining Essentiality Data to Identify Critical Interactions for Cancer Drug Target Discovery and Development

Protein-protein interactions (PPIs) mediate the transmission and regulation of oncogenic signals that are essential to cellular proliferation and survival, and thus represent potential targets for anti-cancer therapeutic discovery. Despite their significance, there is no method to experimentally disrupt and interrogate the essentiality of individual endogenous PPIs. The ability to computationally predict or infer PPI essentiality would help prioritize PPIs for drug discovery and help advance understanding of cancer biology. Here we introduce a computational method (MEDICI) to predict PPI essentiality by combining gene knockdown studies with network models of protein interaction pathways in an analytic framework. Our method uses network topology to model how gene silencing can disrupt PPIs, relating the unknown essentialities of individual PPIs to experimentally observed protein essentialities. This model is then deconvolved to recover the unknown essentialities of individual PPIs. We demonstrate the validity of our approach via prediction of sensitivities to compounds based on PPI essentiality and differences in essentiality based on genetic mutations. We further show that lung cancer patients have improved overall survival when specific PPIs are no longer present, suggesting that these PPIs may be potentially new targets for therapeutic development. Software is freely available at https://github.com/cooperlab/MEDICI. Datasets are available at https://ctd2.nci.nih.gov/dataPortal.

[1]  D. Longo,et al.  Linking β-Catenin to Androgen-signaling Pathway* , 2002, The Journal of Biological Chemistry.

[2]  K. Ha,et al.  Mechanisms underlying TGF‐β1‐induced expression of VEGF and Flk‐1 in mouse macrophages and their implications for angiogenesis , 2007, Journal of leukocyte biology.

[3]  Jing Chen,et al.  NDEx, the Network Data Exchange. , 2015, Cell systems.

[4]  Yun-Wei Lin,et al.  Inhibition of p38 MAPK-Dependent Excision Repair Cross-Complementing 1 Expression Decreases the DNA Repair Capacity to Sensitize Lung Cancer Cells to Etoposide , 2011, Molecular Cancer Therapeutics.

[5]  Jon C. Aster,et al.  Network analysis of gene essentiality in functional genomics experiments , 2015, Genome Biology.

[6]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[7]  F. Staal,et al.  Wnt signaling in leukemias and myeloma: T-cell factors are in control. , 2013, Future oncology.

[8]  Hakho Lee,et al.  Genome-wide CRISPR Screen in a Mouse Model of Tumor Growth and Metastasis , 2015, Cell.

[9]  C. Heldin,et al.  Interaction between Smad7 and beta-catenin: importance for transforming growth factor beta-induced apoptosis. , 2005, Molecular and cellular biology.

[10]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[11]  Pradip De,et al.  Wnt signaling in triple negative breast cancer is associated with metastasis , 2013, BMC Cancer.

[12]  J. Christensen,et al.  Preclinical Development Activation of IL-6 R / JAK 1 / STAT 3 Signaling Induces De Novo Resistance to Irreversible EGFR Inhibitors in Non – Small Cell Lung Cancer with T 790 M Resistance Mutation , 2012 .

[13]  Michael Peyton,et al.  Synthetic lethal screen identification of chemosensitizer loci in cancer cells , 2007, Nature.

[14]  Xiangyin Kong,et al.  Mining for Candidate Genes Related to Pancreatic Cancer Using Protein-Protein Interactions and a Shortest Path Approach , 2015, BioMed research international.

[15]  J. Christensen,et al.  Activation of IL-6R/JAK1/STAT3 Signaling Induces De Novo Resistance to Irreversible EGFR Inhibitors in Non–Small Cell Lung Cancer with T790M Resistance Mutation , 2012, Molecular Cancer Therapeutics.

[16]  A. Marcus,et al.  Wnt-beta-catenin pathway signals metastasis-associated tumor cell phenotypes in triple negative breast cancers , 2016, Oncotarget.

[17]  T. Macdonald,et al.  A functional role for Smad7 in sustaining colon cancer cell growth and survival , 2014, Cell Death and Disease.

[18]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Ellen T. Gelfand,et al.  Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies , 2014, Scientific Data.

[20]  Paul Workman,et al.  Distinctive Behaviors of Druggable Proteins in Cellular Networks , 2015, PLoS Comput. Biol..

[21]  B. Mao,et al.  Hippo/YAP signaling pathway is involved in osteosarcoma chemoresistance , 2016, Chinese journal of cancer.

[22]  R. Nusse,et al.  Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Jiahuai Han,et al.  p38γ regulates UV-induced checkpoint signaling and repair of UV-induced DNA damage , 2010, Protein & Cell.

[24]  István A. Kovács,et al.  Widespread Macromolecular Interaction Perturbations in Human Genetic Disorders , 2015, Cell.

[25]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[26]  Y. Benjamini,et al.  THE CONTROL OF THE FALSE DISCOVERY RATE IN MULTIPLE TESTING UNDER DEPENDENCY , 2001 .

[27]  F. Khuri,et al.  Targeting protein-protein interactions as an anticancer strategy. , 2013, Trends in pharmacological sciences.

[28]  Randall T. Moon,et al.  The transcriptional coactivator CBP interacts with beta-catenin to activate gene expression. , 2000, The Journal of cell biology.

[29]  Reuven Agami,et al.  A large-scale RNAi screen in human cells identifies new components of the p53 pathway , 2004, Nature.

[30]  M. Vidal,et al.  Edgetic perturbation models of human inherited disorders , 2009, Molecular systems biology.

[31]  Hui Zhang,et al.  TGFβ signaling in pancreatic ductal adenocarcinoma , 2015, Tumor Biology.

[32]  C. Tse,et al.  ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. , 2008, Cancer research.

[33]  Michael Peyton,et al.  Systematic Identification of Molecular Subtype-Selective Vulnerabilities in Non-Small-Cell Lung Cancer , 2013, Cell.

[34]  M. Kahn,et al.  Safely targeting cancer stem cells via selective catenin coactivator antagonism , 2014, Cancer science.

[35]  Kenneth H. Buetow,et al.  PID: the Pathway Interaction Database , 2008, Nucleic Acids Res..

[36]  J. Mesirov,et al.  Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer , 2011, Proceedings of the National Academy of Sciences.

[37]  Dihua Yu,et al.  Overexpression of 14-3-3ζ in cancer cells activates PI3K via binding the p85 regulatory subunit , 2011, Oncogene.

[38]  J. Mesirov,et al.  GenePattern 2.0 , 2006, Nature Genetics.

[39]  A. Khwaja,et al.  Constitutive activation of the Wnt/β-catenin signalling pathway in acute myeloid leukaemia , 2005, Oncogene.

[40]  Jeffrey R. Whiteaker,et al.  Proteogenomic characterization of human colon and rectal cancer , 2014, Nature.

[41]  Sergey Brin,et al.  Reprint of: The anatomy of a large-scale hypertextual web search engine , 2012, Comput. Networks.

[42]  Alok J. Saldanha,et al.  Java Treeview - extensible visualization of microarray data , 2004, Bioinform..

[43]  C. Moreno,et al.  Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells , 2013, Journal of Translational Medicine.

[44]  Hyeong Jun An,et al.  Estimating the size of the human interactome , 2008, Proceedings of the National Academy of Sciences.

[45]  M. Schlissel,et al.  Activation of p38 MAP kinase by DNA double‐strand breaks in V(D)J recombination induces a G2/M cell cycle checkpoint , 2006, The EMBO journal.

[46]  C. Roberts,et al.  Vulnerabilities of mutant SWI/SNF complexes in cancer. , 2014, Cancer cell.

[47]  Fengzhu Sun,et al.  A network-based integrative approach to prioritize reliable hits from multiple genome-wide RNAi screens in Drosophila , 2009, BMC Genomics.

[48]  E. Shimizu,et al.  Synergistic cell growth inhibition by the combination of amrubicin and Akt-suppressing tyrosine kinase inhibitors in small cell lung cancer cells: implication of c-Src and its inhibitor. , 2009, International journal of oncology.

[49]  G. Ganji,et al.  BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor Models , 2013, PloS one.

[50]  C. Heldin,et al.  Interaction between Smad7 and β-Catenin: Importance for Transforming Growth Factor β-Induced Apoptosis , 2005, Molecular and Cellular Biology.

[51]  Jenny J. Li,et al.  A Review: Molecular Aberrations within Hippo Signaling in Bone and Soft-Tissue Sarcomas , 2015, Front. Oncol..

[52]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[53]  William B. Smith,et al.  Selective inhibition of BET bromodomains , 2010, Nature.

[54]  K. Wisinski,et al.  Role of the androgen receptor in triple-negative breast cancer. , 2016, Clinical advances in hematology & oncology : H&O.

[55]  W. Hahn,et al.  ARID1B is a specific vulnerability in ARID1A-mutant cancers , 2014, Nature Medicine.

[56]  C. Schaefer,et al.  Genome-wide shRNA screen reveals increased mitochondrial dependence upon mTORC2 addiction , 2011, Oncogene.

[57]  K. Matsumoto,et al.  Phosphorylation of the retinoblastoma protein by cdk2. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[58]  J. Potter,et al.  Genetic Variations in SMAD7 Are Associated with Colorectal Cancer Risk in the Colon Cancer Family Registry , 2013, PloS one.

[59]  René Bernards,et al.  An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors , 2006, Nature chemical biology.

[60]  W. Isaacs,et al.  In vitro evidence for complex modes of nuclear β-catenin signaling during prostate growth and tumorigenesis , 2002, Oncogene.

[61]  E. Schadt,et al.  Integrating siRNA and protein-protein interaction data to identify an expanded insulin signaling network. , 2009, Genome research.

[62]  Pablo Tamayo,et al.  ATARiS: Computational quantification of gene suppression phenotypes from multisample RNAi screens , 2013, Genome research.

[63]  W. Hahn,et al.  ARID1B is a specific vulnerability in ARID1A-mutant cancers , 2014, Nature Medicine.

[64]  E. Llamosas,et al.  Wnt signalling in gynaecological cancers: A future target for personalised medicine? , 2016, Gynecologic oncology.

[65]  Jih-Hsiang Lee,et al.  The Janus Kinases Inhibitor AZD1480 Attenuates Growth of Small Cell Lung Cancers In Vitro and In Vivo , 2013, Clinical Cancer Research.

[66]  R. Beroukhim,et al.  BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma , 2013, Clinical Cancer Research.

[67]  L. Vassilev,et al.  Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. , 2005, Blood.

[68]  Jill P. Mesirov,et al.  β-Catenin-Driven Cancers Require a YAP1 Transcriptional Complex for Survival and Tumorigenesis , 2012, Cell.

[69]  Khalique Newaz,et al.  Identification of Major Signaling Pathways in Prion Disease Progression Using Network Analysis , 2015, PloS one.